Bionano Genomics ( (BNGO) ) has released its Q2 earnings. Here is a breakdown of the information Bionano Genomics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bionano Genomics is a company specializing in genome analysis solutions, offering optical genome mapping (OGM) systems, diagnostic services, and software for research and clinical applications. The company is recognized for its innovative approach to genome analysis and its platform-agnostic software solutions.
In its latest earnings report for the second quarter of 2025, Bionano Genomics highlighted a strategic shift towards focusing on routine users of its OGM systems and software, which has resulted in a gross margin increase to over 50%. Despite a 13% decrease in total revenue compared to the same period last year, the company saw a rise in consumables and software revenues by 16% and an 11% increase in adjusted combined revenue.
Key financial metrics for the quarter included a total revenue of $6.7 million, a significant improvement in gross margin from 33% to 52%, and a reduction in operating expenses by 42%. The company also reported a 17% increase in the sale of nanochannel array flowcells and a 4% increase in the installed base of OGM systems. Recent business highlights included software upgrades and a record number of peer-reviewed publications, underscoring the growing adoption of OGM technology.
Looking ahead, Bionano Genomics maintains its full-year revenue guidance between $26.0 to $30.0 million and anticipates increased installations of OGM systems. The company aims to continue leveraging its cost-saving initiatives and capital efficiency to sustain its operations into early 2026.